Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy

Genetic risks in breast cancer remain only partly understood. Here we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Ingle, James N., Xie, Fang, Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Chapman, Judith-Anne W., Chen, Bingshu E., Kubo, Michiaki, Furukawa, Yoichi, Momozawa, Yukihide, Stearns, Vered, Pritchard, Kathleen I., Barman, Poulami, Carlson, Erin E., Goetz, Matthew P., Weinshilboum, Richard M., Kalari, Krishna R., Wang, Liewei
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5135610/
https://ncbi.nlm.nih.gov/pubmed/27758888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1371
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares